Antara Capital’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

Antara Capital’s Portfolio ICPT Stock Details ICPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-83,926	Closed	-$2.07M	–	132
2020 Q4	$2.07M	Buy	+83,926	New	+$2.78M	0.43%	24
2020 Q1	–	Sell	-23,700	Closed	-$2.94M	–	56
2019 Q4	$2.94M	Buy	+23,700	New	+$2.12M	0.6%	34

Other funds holding ICPT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Antara Capital's ICPT Position: Q1 2021 in Review

Antara Capital sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q1 2021, closing a stake of 83,926 shares — an estimated $2.07M sold.

Antara Capital first reported a position in ICPT in Q4 2019 and held it in 2 quarters. The position peaked at $2.94M in Q4 2019. 151 funds tracked by Wall St. Rank hold ICPT as of Q1 2021.

Antara Capital reported no remaining Intercept Pharmaceuticals, Inc. position as of Q1 2021 after selling out during the quarter.
Antara Capital sold 83,926 Intercept Pharmaceuticals, Inc. shares in Q1 2021, an estimated $2.07M.
Antara Capital first reported a position in Intercept Pharmaceuticals, Inc. in Q4 2019 and held it in 2 quarters.
Antara Capital's Intercept Pharmaceuticals, Inc. position peaked at $2.94M in Q4 2019.
151 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q1 2021.

Based on Antara Capital's 13F filing for Q1 2021, filed 17 May 2021.